BOND
17 evidence topics · 2 sources
Objective
Registered study purpose
Location and study date
Registered study dates and sites
| Field | Quoted record |
|---|---|
| Study start | “2014-03” |
| Primary completion (actual) | “2016-06” |
| Number of sites | “This study has 7 locations” |
| Study chair | “Alex W Yeung, MBBS” |
Study design
Registered design: integrated phase 2/3 randomized controlled trial
Registered design details
| Field | Quoted record |
|---|---|
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |
Eligibility criteria
Inclusion: high-grade disease with carcinoma in situ after BCG
Inclusion: cystectomy indicated, age, and performance status
Exclusion criteria
Treatment
Experimental arm: CG0070 after DDM pretreatment
Control arm: investigator choice of intravesical chemotherapy or interferon
Study outcomes
Rationale for using complete response as the primary endpoint
Registered primary endpoint, phase 2 part: complete response at 9 months
Registered primary endpoint, phase 3 part: durable complete response at 15 months
Regulatory context for durable complete response in single-arm trials
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
| Field | Quoted record |
|---|---|
| Enrollment (actual) | “22” |
Planned between-arm comparisons
Description of analysis sets
No evidence found.
Results
Participant disposition
Study termination
| Field | Quoted record |
|---|---|
| Reason for stopping | “Change in study design” |
| Study completion (actual) | “2016-06” |
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: limitations of BOND
- BOND was registered as an integrated phase 2/3, open-label, randomized study of CG0070 against investigator choice of mitomycin C, interferon, valrubicin, or gemcitabine in participants with CIS-containing disease after BCG.
- The registry lists the study as terminated for a “Change in study design” with 22 participants enrolled, from March 2014 to June 2016.
- No results posted on ClinicalTrials.gov and no publication or company report of its efficacy or safety results were identified, so the study contributes no efficacy or safety data to this report.
- Eligibility allowed participants who had been “successfully treated with BCG, but subsequently found to have recurrence”, so the registered population differs from the BCG-unresponsive population of BOND-003.